MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

597.4M

Vuru Grade

31.00/100

Current Price

$11.58
+0.58 (+5.27%)

Stability Price

$0.30
Overvalued by 97.38%

Company Metrics

  • 13.83 P/E
  • 12.95 P/S
  • 2.83 P/B
  • -2.193 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 537,544.00 Avg. Vol.
  • 51.59M Shares
  • 597.4M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

momenta pharmaceuticals inc
Businessweek - Jun 26, 2012
Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs.
Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc. (Fed. Cir ...
Patent Docs - Aug 10, 2012
Momento Pharmaceuticals The case involved a District Court grant of a preliminary injunction to Momenta in litigation between two ANDA filers.
Momenta Pharmaceuticals Inc. v. Amphastar Pharmaceuticals, Inc.: "The Rest of ...
Patent Docs - Aug 14, 2012
Chief Judge Rader Judge Rader wrote a vigorous dissent to the panel majority's opinion in Momenta v. Amphastar, disagreeing with the panel majority's interpretation that the "safe harbor" embodied in 35 U.S.
Limitation On Future Patent Protection For Biosimilars? - Mondaq News Alerts (registration)
Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA)
TheStreet.com - Mar 4, 2014
This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the ...
Momenta Pharmaceuticals Director Bennett M. Shapiro Sells 5800 Shares (MNTA)
WKRB News - 22 hours ago
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Wednesday, November 5th. The company reported ($0.56) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.43) by $0.13.
Momenta Pharmaceuticals Stock Price Down 5.2% After Insider Selling (MNTA) - Ticker Report
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank ...
GlobeNewswire (press release) - Nov 24, 2014
CAMBRIDGE, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 ...
Momenta Pharmaceuticals Heading For A Repeat
Seeking Alpha (registration) - Aug 5, 2014
More importantly going forward, Momenta's 50% share of profits could fill the company's coffers with enough coin to allow further development of proprietary candidates like necuparanib.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results
MarketWatch - Nov 5, 2014
Momenta Pharmaceuticals, Inc. MNTA, -2.89% a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the third quarter ended September 30, 2014.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5%
Zacks.com - Oct 13, 2014
Momenta Pharmaceuticals Inc. (MNTA - Snapshot Report) saw a big move last session, as the company's shares fell by almost 14% on the day.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit ...
Seeking Alpha (registration) - Nov 13, 2014
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript). Nov. 12, 2014 7:39 PM ET | About: Momenta Pharmaceuticals, Inc. (MNTA) by: SA Transcripts. Momenta Pharmaceuticals, Inc.